Výsledky vyhledávání - "Ginevra, Fiori"

Akademický článek

Switching from originator adalimumab to biosimilar SB5 in a rheumatology cohort: persistence on treatment, predictors of drug interruption and safety analysis

Autor: Cosimo Bruni, Stefano Gentileschi, Giovanni Pacini, Marco Bardelli, Lorenzo Tofani, Francesca Bartoli, Caterina Baldi, Laura Cometi, Ginevra Fiori, Francesca Nacci, Luca Cantarini, Serena Guiducci, Alberto Moggi-Pignone, Bruno Frediani, Marco Matucci-Cerinic

Publikováno v: Therapeutic Advances in Musculoskeletal Disease, Vol 13 (2021)

Aims: Medical and non-medical switching strategies have been adopted in Europe in the last few years. We aimed to investigate persistence on treatment with a SB5 Adalimumab (SB5) biosimilar after switching from Adalimumab (ADA) originator among patie

Externí odkaz: https://doaj.org/article/c82ec4d5c5804403a16b1317eb025061

Zobrazit plný text záznamu

Akademický článek

Baricitinib in the treatment of rheumatoid arthritis: clinical and ultrasound evaluation of a real-life single-centre experience

Autor: Giulia Tesei, Laura Cometi, Francesca Nacci, Riccardo Terenzi, Lorenzo Tofani, Marco Capassoni, Francesca Bartoli, Ginevra Fiori, Marco Matucci-Cerinic, Cosimo Bruni

Publikováno v: Therapeutic Advances in Musculoskeletal Disease, Vol 13 (2021)

Background: Ultrasound (US) is useful in monitoring RA patients, with the US7 score allowing grey-scale and power-Doppler (PD) semi-quantitative evaluation of synovitis and teno-synovitis. We evaluated real-life efficacy and safety of Baricitinib, an

Externí odkaz: https://doaj.org/article/e51503846e3e41a1acac156a1e1f23c3

Zobrazit plný text záznamu

Akademický článek

The switch from etanercept originator to SB4: data from a real-life experience on tolerability and persistence on treatment in joint inflammatory diseases

Autor: Cosimo Bruni, Stefano Gentileschi, Giovanni Pacini, Caterina Baldi, Marco Capassoni, Lorenzo Tofani, Marco Bardelli, Laura Cometi, Luca Cantarini, Francesca Nacci, Michele Vietri, Francesca Bartoli, Ginevra Fiori, Bruno Frediani, Marco Matucci-Cerinic

Publikováno v: Therapeutic Advances in Musculoskeletal Disease, Vol 12 (2020)

Aims: Switching from originator to biosimilar is part of current practice in inflammatory rheumatic musculoskeletal diseases (iRMDs) such as rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondylarthritis (axSpA), with evidences deriv

Externí odkaz: https://doaj.org/article/c897c72d48d5467880eaf49ed3edc699

Zobrazit plný text záznamu

The positive side of the coin: Sars-Cov-2 pandemic has taught us how much Telemedicine is useful as standard of care procedure in real life

Autor: Laura Cometi, Maria Letizia Conforti, Martina Orlandi, Khadija El Aoufy, Laura Rasero, Francesca Bartoli, Francesca Nacci, Jelena Blagojevic, Serena Guiducci, Alberto Moggi-Pignone, Marco Matucci-Cerinic, Maria Ramona Melis, Ginevra Fiori, Cosimo Bruni, Silvia Bellando Randone

Publikováno v: Clinical Rheumatology

Patients and health workers were at high risk of infection during the Sars-Cov-2 pandemic lockdown. For this reason, other medical and clinical approaches such as Telemedicine were necessary. Despite Telemedicine was born before COVID-19, the pandemi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c11e61b9afdd3083bbbe59384815c357
http://europepmc.org/articles/PMC8569841

Zobrazit plný text záznamu

Persistence of remission after lengthening of golimumab in inflammatory joint diseases

Autor: Arianna, Damiani, Francesca, Bartoli, Giovanni, Pacini, Davide, Carboni, Silvia, Bellando Randone, Ginevra, Fiori, Marco, Matucci-Cerinic, Serena, Guiducci

Publikováno v: Clinical and Experimental Rheumatology.

In refractory inflammatory joint diseases (IJDs) biological disease-modifying anti-rheumatic drugs (bDMARDs) may achieve remission. EULAR recommends bDMARD tapering when remission persists. However, guidelines on tapering modalities and criteria for

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90e94e388d0b2159eb6459c582d59e64
https://doi.org/10.55563/clinexprheumatol/k76z51

Zobrazit plný text záznamu

The switch from etanercept originator to SB4: data from a real-life experience on tolerability and persistence on treatment in joint inflammatory diseases

Autor: Michele Vietri, Francesca Bartoli, Marco Matucci-Cerinic, Bruno Frediani, Ginevra Fiori, Cosimo Bruni, Laura Cometi, Lorenzo Tofani, Caterina Baldi, Marco Bardelli, Giovanni Pacini, Marco Capassoni, Francesca Nacci, Stefano Gentileschi, Luca Cantarini

Publikováno v: Therapeutic Advances in Musculoskeletal Disease
Therapeutic Advances in Musculoskeletal Disease, Vol 12 (2020)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38256a488bd390de082a94ebf5ec8886
http://europepmc.org/articles/PMC7576915

Zobrazit plný text záznamu

Efficacy and safety of switching from reference adalimumab to SB5 in a real-life cohort of inflammatory rheumatic joint diseases

Autor: Francesca Bartoli, Roberta Bitti, Marco Matucci-Cerinic, Francesca Nacci, Ginevra Fiori, Cosimo Bruni, Lorenzo Tofani, Laura Cometi

Publikováno v: Clinical rheumatology. 40(1)

SB5 showed comparable efficacy and safety profile in respect to adalimumab originator (ADA) in randomized clinical trials of rheumatoid arthritis (RA) and psoriasis. We aimed to describe the efficacy and safety of SB5 after switching from ADA in RA,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b407f4e4a0a801479f400c279c704dc5
https://pubmed.ncbi.nlm.nih.gov/32514676

Zobrazit plný text záznamu

Effect of Dysmetabolisms and Comorbidities on the Efficacy and Safety of Biological Therapy in Chronic Inflammatory Joint Diseases

Autor: Nicolò Chiti, Lorenzo Tofani, Serena Guiducci, Francesca Bartoli, Cosimo Bruni, Marco Matucci-Cerinic, Ginevra Fiori, Daniela Melchiorre, Laura Cometi, Francesca Nacci, Silvia Bellando-Randone

Publikováno v: Journal of Clinical Medicine
Journal of Clinical Medicine, Vol 9, Iss 1310, p 1310 (2020)
Volume 9
Issue 5

In the present study we evaluated how systemic arterial hypertension (SAH), dyslipidemia and diabetes mellitus influence the efficacy, safety and retention rate of biological disease-modifying anti-rheumatic drug (bDMARD) treatment in rheumatic muscu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a5ebdc0a747eb257b92cf8d02347b5e
http://hdl.handle.net/2158/1192799

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání